- Open
- 35.00
- High
- 35.23
- Low
- 34.00
- Close
- 35.23
- Change
- -1.00 (-2.86%)
- Volume
- 19,188
| 10 Sept 2026 | 07:00:00 | Faron Announces R&D Day |
| 7 Sept 2026 | 16:30:00 | HOLDING(S) IN COMPANY |
| 4 Sept 2026 | 11:00:00 | HOLDING(S) IN COMPANY |
| 27 Aug 2026 | 07:00:00 | Faron Announces First Patient Enrolled in BEXAR Investigator-Initiated Trial |
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat cancers. Its lead product, bexmarilimab, is an investigational humanized antibody designed to target the Clever-1 receptor on macrophages, aiming to reprogram myeloid cell function and enhance immune responses against tumors. Faron conducts clinical trials for bexmarilimab in combination with standard treatments for hematological malignancies, including acute myeloid leukemia and myelodysplastic syndrome. The company operates globally, seeking to expand the accessibility of immunotherapy for cancer patients.
| 10 Sept 2026 | 07:00:00 | Faron Announces R&D Day |
| 7 Sept 2026 | 16:30:00 | HOLDING(S) IN COMPANY |
| 4 Sept 2026 | 11:00:00 | HOLDING(S) IN COMPANY |
| 27 Aug 2026 | 07:00:00 | Faron Announces First Patient Enrolled in BEXAR Investigator-Initiated Trial |
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat cancers. Its lead product, bexmarilimab, is an investigational humanized antibody designed to target the Clever-1 receptor on macrophages, aiming to reprogram myeloid cell function and enhance immune responses against tumors. Faron conducts clinical trials for bexmarilimab in combination with standard treatments for hematological malignancies, including acute myeloid leukemia and myelodysplastic syndrome. The company operates globally, seeking to expand the accessibility of immunotherapy for cancer patients.
| 26 Aug 2026 | 07:00:00 | Half-year financial results 1 January – 30 June 2026 |
| 26 Aug 2026 |
| Faron targets second-half start for pivotal blood cancer trial after latest investment round |
| 26 Aug 2026 | 07:00:00 | Half-year financial results 1 January – 30 June 2026 |
| 26 Aug 2026 |
| Faron targets second-half start for pivotal blood cancer trial after latest investment round |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £194.31bn | +0.1% | |
| £81.34bn | +0.3% | |
| £1.79bn | -0.2% | |
| £33m | — | |
| £21m | -0.7% | |
FARNFaron Pharmaceuticals OY | £19m | -0.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £194.31bn | +0.1% | |
| £81.34bn | +0.3% | |
| £1.79bn | -0.2% | |
| £33m | — | |
| £21m | -0.7% | |
FARNFaron Pharmaceuticals OY | £19m | -0.8% |
